Bioxcel therapeutics announces initiation of serenity at-home pivotal phase 3 safety trial of bxcl501 for acute treatment of agitation associated with bipolar disorders or schizophrenia

E stimated 23 million annual agitation episodes in the at-home setting 1-3   no fda-approved therapies in the at-home setting for acute treatment of agitation associated with bipolar disorders or schizophrenia new haven, conn., sept. 05, 2024 (globe newswire) -- bioxcel therapeutics, inc. (nasdaq: btai), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced the initiation of patient enrollment in its serenity at-home pivotal phase 3 trial.
BTAI Ratings Summary
BTAI Quant Ranking